EFdA (4 0 -ethynyl-2-fluoro-2 0 -deoxyadenosine), a nucleoside reverse transcriptase inhibitor with extremely potent anti-HIV activity, was concisely synthesized from (R)-glyceraldehyde acetonide in an 18% overall yield by a 12-step sequence involving highly diastereoselective ethynylation of an -alkoxy ketone intermediate. The present synthesis is superior, both in overall yield and in the number of steps, to the previous one which required 18 steps from an expensive starting material and resulted in a modest overall yield of 2.5%.
Since the first approval of zidovudine (also called azidothymidine, AZT) for clinical use in 1987, seven additional nucleoside reverse transcriptase inhibitors (NRTIs), including abacavir (ABC) and tenofovir (TNF), have been approved and prescribed for people infected by human immunodeficiency virus (HIV) or patients suffering from acquired immunodeficiency syndrome (AIDS) caused by HIV infection (Fig. 1 ). 1, 2) All of the furanose or pseudofuranose portions in the eight NRTIs are structurally devoid of the 3 0 -hydroxyl (3 0 -OH) group which is present in natural nucleosides and is indispensable for DNA chain elongation by viral reverse transcriptases (RTs). Therefore, once incorporated as their 6 0 -monophosphate into the 3 0 -terminus of a viral DNA primer, the nucleoside analogs without the 3 0 -OH functionality block further nucleotide addition by RTs, and thereby serve as obligate DNA chain elongation terminators. 3, 4) The absence of the 3 0 -OH group has long been considered to be a prerequisite for NRTIs to exert anti-HIV activity, probably due to the reasonable and readily understandable mode of action. 5) In recent years, however, it has been revealed that nucleoside derivatives bearing the 3 0 -OH group also exhibited significant anti-HIV activity by inhibiting viral reverse transcriptases through several mechanisms of action.
3) Among the NRTIs with the 3 0 -OH group, EFdA [4 0 -ethynyl-2-fluoro-2 0 -deoxyadenosine (1), also abbreviated as 4
0 Ed2FA], designed by Ohrui and co-workers stands out as a promising anti-HIV agent. [6] [7] [8] [9] [10] [11] Their modification made at two positions (2 and 4 0 ) of the parent natural nucleoside 2 0 -deoxyadensine endowed 1 with the following remarkable pharmacological profiles: (i) exceptionally potent inhibitory activity against HIV-1 replication [e.g., EC 50 for HIV-1 NL4-3 ¼ 50 pM in phytohemagglutinin-activated peripheral blood mononuclear cells (PBMCs), which is several orders of magnitude more effective than that of any currently prescribed NRTIs such as AZT (22 nM) and TNF (3300 nM)]; 5) (ii) excellent in vitro selectivity indices (SI ¼ CC 50 /EC 50 ; e.g., >200,000 for HIV-1 NL4-3 in PBMCs, and 134,000 for HIV-1 IIIB in MT-4 cells), which are superior to that of AZT (SI ¼ 10;800 for HIV-1 IIIB in MT-4 cells); 5, 12, 13) (iii) no acute toxicity toward ICR mice at a dose of 100 mg/kg; 6, 14) (iv) retention of efficacy even against a wide spectrum of drug-resistant HIV-1 variants including multidrug-resistant clinical isolates; [12] [13] [14] and (v) longer intracellular half-life value (t 1=2 , 17.2 h) in its active form (EFdA-5 0 -triphosphate) than that of AZT-5 0 -triphosphate (2.8 h) which may enable a once-daily or twice-daily regimen. 13) From these favorable properties, EFDA (1), which is currently under preclinical evaluation, is attracting rising attention as a potential therapeutic agent for HIV-infected patients. 3, 4) In contrast to the various biological and medicinal studies on 1 that have been progressively reported, there has been only one way to supply EFdA (1), the synthesis by Kohgo and co-workers which required a considerably lengthy 18-step sequence from the expensive starting material, 2-amino-2 0 -deoxyadenosine, resulting in a modest overall yield of 2.5%. 6, 7) The limited availability of 1 as well as its promising pharmacological profiles just described prompted our synthetic efforts to supply a sufficient amount of 1 to further promote its biological and clinical research. These efforts have recently culminated in an enantioselective 12-step total synthesis of 1 in an 18% overall yield from the simple starting material, (R)-glyceraldehyde acetonide. 15) We describe in this article a full account of our total synthesis of 1, including some unsuccessful attempts.
Results and Discussion
Our synthetic plan for EFdA (1) is shown in Scheme 1. We considered that the target molecule (1) would be obtained via N-glycosidation of activated 2 0 -deoxyfuranose derivative 2 with 2-fluoroadenine 3,
y To whom correspondence should be addressed. Fax: +81-22-717-8783; E-mail: skuwahar@biochem.tohoku.ac.jp Abbreviations: BSA, N,O-bis(trimethylsilyl)acetamide; DMAP, 4-(dimethylamino)pyridine; DMP, Dess-Martin's periodinane; EDCI, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; MOM, methoxymethyl; MTPA, -methoxy--(trifluoromethyl)phenylacetyl; PPTS, pyridinium p-toluenesulfonate; TBDPS, tert-butyldiphenylsilyl; Tf, trifluoromethanesulfonyl; TIPS, triisopropylsilyl; TMS, trimethylsilyl which in turn is commercially available or readily obtainable from 2,6-diaminopurine in a single step. 16, 17) Glycosyl donor 2 could be prepared by oxidative cleavage of the terminal double bond of 4, followed by spontaneous hemiacetal ring formation and subsequent activation of the resulting anomeric hydroxy group. To appropriately install the stereochemistry at the C4 0 position of 4, we planned to use diastereoselective addition of an acetylene derivative to suitably protected hydroxy ketone 5 which could be obtained from the well-known chiral building block, (R)-glyceraldehyde acetonide (6) , by diastereoselective allylation coupled with some functional group manipulations.
To achieve high diastereoselectivity in the ethynylation step of our synthetic plan (5 ! 4 in Scheme 1), we chose known MOM-protected acetal 7 [18] [19] [20] as the starting point (Scheme 2), since our literature search revealed that the addition of acetylide anions tohydroxy ketones would proceed with high diastereoselectivity when the hydroxy group was protected as its MOM ether. 21, 22) Compound 7 was readily obtained from 6 in two steps, comprising highly diastereoselective allylation of 6 with allylzinc bromide and MOMprotection of the resulting alcohol according to the literature. [18] [19] [20] Selective deprotection of the acetonide group of 7 was conducted by its treatment with PPTS in aqueous methanol to form 8, the primary hydroxy group of which was then protected as its TBDPS ether 9. Swern oxidation of 9 gave MOM-protected ketone 10, which was then subjected to an addition reaction with (triisopropylsilyl)ethynylmagnesium bromide to afford acetylenic alcohol 11 as a single diastereomer. The stereochemistry of 11 was determined later at the stage of 2a by observing a diagnostic NOE correlation between the C3 0 proton and the C5 0 protons (see structure 2a in Scheme 2). This complete stereoselectivity in the formation of 11 would be explained by assuming chelation-controlled transition state 10 0 depicted in Scheme 2; the acetylenic nucleophile would approach the C4 0 carbonyl from its less-hindered siface. 21) Ozonolysis of 11 and subsequent spontaneous cyclization proceeded uneventfully to give furanose derivative 12, the anomeric hydroxy group of which was then activated by acetylation to furnish glycosyl donor 2a. N-Glycosidation of 2a with 2-fluoroadenine 3 was implemented under the silyl-Hilbert-Johnson reaction conditions. [23] [24] [25] Fluorinated nucleobase 3 (1.6 eq.) was thus treated for 4 h with a silylating agent [BSA (13), 1.9 eq.] and Lewis acid (TMSOTf, 1.8 eq.) in refluxing MeCN to generate the corresponding silylated nucleobase, which was then allowed to react with 2a at refluxing temperature for 2 h to give a mixture of 14 (1) To improve the diastereoselectivity of the N-glycosidation process, we next attempted a highly stereoselective method for preparing 2 0 -deoxy--ribonucleosides that has recently been reported by Zhang and co-workers. 26) As shown in Fig. 2 , this method takes advantage of the N-acetylglycinate residue at the C3 0 position of 2 0 -deoxyfuranose derivative A as a stereodirecting group, giving -N-glycoside C with high diastereoselectivity (up to 98%) via the formation of oxocarbenium ion intermediate B stabilized intramolecularly by the N-acetylglycinate residue. Scheme 3 outlines the preparation of glycosyl donor 2b bearing the stereo-directing group. The MOM protecting group of 11 was selectively removed by treating with ZnBr 2 and 1-dodecanethiol in CH 2 Cl 2 27,28) to give diol 15. The esterification of 15 with N-acetylglycine in the presence of EDCI and DMAP proceeded considerably sluggishly, affording 16 in a 67% yield [94% based on the recovered starting material (brsm)] after reacting at room temperature for 13 h. Ozonolysis of 16 and subsequent acetylation of lactol intermediate 17 afforded 2b which was then subjected to N-glycosidation with 3. As shown in Table 1 , the N-glycosidation of 2b with a silylated nucleobase generated from 3 in dichloroethane, which had been used as the solvent in the reported protocol, 26) exhibited no stereoselectivity, giving a mixture of 18 and 18 in a ratio of ca. 1:1 with an unsatisfactory yield of 21% (entry 1). The use of CH 3 CN, a solvent often used for this type of N-glycosidation, 25, 29, 30) or toluene, a typical solvent for Lewis acid-mediated reactions, did not improve the diastereoselectivity at all, affording a ca. 1:1 mixture of 18 and 18 in both cases (entries 2 and 3). The poor diastereoselectivity in the N-glycosidation of 2b might be ascribable, in part, to the difficulty in the formation of transition state B 0 (Fig. 3) , in which the -oriented acetylenic substituent at the C4 0 position is located on the sterically congested concave side of the pseudo-bicyclic ring system. a A mixture of 3, BSA, and TMSOTf in the solvent indicated was refluxed for 4 h. To the resulting mixture was added a solution of 2b in the same solvent at 0 C, and the mixture was stirred at room temperature for the time indicated.
Aiming to reduce the steric bulkiness of the C4 0 acetylenic substituent, we next planned to subject sterically less demanding glycosyl donor 2c (Scheme 4), which is devoid of the bulky triisopropyllsilyl moiety, to the N-glycosidation reaction. An outline of the preparation of 2c is shown in Scheme 4. Dess-Martin oxidation of compound 9 and subsequent addition of (trimethylsilyl)ethynylmagnesium bromide to resulting ketone 10 gave 19 as a single diastereomer. Methanolytic removal of the TMS group of 19 afforded 20. Its MOM group was then deprotected to give diol 21, whose enantiomeric excess was evaluated to be >95% by a 1 H-NMR analysis of corresponding (R)-and (S)-3 0 -mono-MTPA esters 22. Acylation of the secondary hydroxy group of 21 with N-acetylglycine went to completion by stirring the reaction mixture for 12 h at room temperature, and provided 23 in an 89% yield which contrasts with the sluggishness in the acylation of corresponding TIPS-protected diol 15 (see Scheme 3). Finally, ozonolysis of 23 and subsequent acetylation of resulting lactol 24 provided 2c which was subjected to an N-glycosidation reaction with 3 ( Table 2 ). All of the reactions in Table 2 were conducted by using CH 3 CN as a solvent, since preliminary experiments indicated that lesser amounts of undesired impurities were produced in CH 3 CN than in other solvents. Table 2 shows that the N-glycosidation of 2c with 3, under analogous conditions to those employed in entry 2 of Table 1 
The experiments conducted so far revealed the poor diastereoselectivity in the N-glycosidation of the glycosyl donors (2a, 2b and 2c), exhibiting an / selectivity of 1:2 at best as shown in Table 2 . We therefore finally decided to prioritize the conciseness of the synthetic route over the diastereoselectivity of the N-glycosidation step. The modified synthetic route is shown in Scheme 5. Compound 21 was exposed to ozonolysis conditions to give cyclic hemiacetal 27 as an anomeric mixture. The ratio of the -anomer to -anomer was 2.8:1 as judged by
(i-Pr) 3 Si H Scheme 4. Preparation of Glycosyl Donor 2c. Table 2 . N-Glycosylation of 2c the 1 H-NMR analysis; the stereochemistry of each anomer was determined from the NOEs indicated in Scheme 5 for -anomer 27. The two hydroxy groups of 27 were acetylated to afford glycosyl donor 2d as a 1:1.4 anomeric mixture, favoring the -anomer in this case; the stereochemistry of the anomers (2d and 2d) was determined by observing the NOEs indicated in Scheme 5. N-Glycosidation of 2d with 3 under analogous conditions to those employed in entry 2 of Table 2 proceeded considerably cleanly, furnishing a 1.6:1 mixture of -anomer 28 and the correspondinganomer; in this case, no corresponding N 6 -silylated products were obtained (cf. 26 in Table 2 ). Chromatographic purification of the mixture gave 28 in a 46% isolated yield together with the -anomer (25%). Finally, the two protecting groups of 27 were easily removed by successively treating with NH 4 F 33,34) and a methanolic solution of NaOH in one pot, providing EFdA (1) as a white crystalline solid [mp 220.0-221.4 C (dec.)] in a good yield of 87%. The 1 H-NMR spectrum of 1 was identical with that of an authentic sample of EFdA.
In conclusion, the enantioselective total synthesis of EFdA (1) was accomplished in an 18% overall yield from commercially available protected aldehyde 6 via 12 steps, this being much better both in overall yield and in the number of steps than the previous synthesis by Kohgo and co-workers (2.5% overall yield in 18 steps from 2-amino-2 0 -deoxyadenosine). Attempts to improve the diastereoselectivity of the N-glycosidation step as well as to convert the undesired -anomer of 28 into desired anomer 28 in the presence of various Lewis acids are currently underway and will be reported in due course.
Experimental
IR spectra were recorded by a Jasco FT/IR-4100 spectrometer, using an ATR (ZnSe) attachment, and are reported in cm À1 . NMR spectra were recorded with TMS as an internal standard in CDCl 3 by a Varian MR-400 spectrometer (400 MHz for 1 H and 100 MHz for 13 C) or a Varian 600TT spectrometer (600 MHz for 1 H and 125 MHz for 13 C) unless otherwise stated. Optical rotation values were measured with a Jasco DIP-371 polarimeter or a Horiba Septa-300 polarimeter, and the mass spectra were obtained with a Jeol JMS-700 spectrometer operated in the FAB mode. Melting point (mp) data were determined with Yanaco MP-J3 apparatus and are uncorrected. Merck silica gel 60 (7-230 mesh) was used for column chromatography unless otherwise stated. All solvents for the reactions were distilled prior to use: THF from Na and benzophenone; MeOH from Mg and I 2 ; and CH 2 Cl 2 , MeCN and DMF from CaH 2 . (2R,3S)-1-(tert-Butyldiphenylsilyloxy)-3-methoxymethoxy-5-hexen-2-ol (9) . To a stirred solution of 8 (4.03 g, 22.9 mmol) in DMF (110 mL) were successively added imidazole (3.89 g, 57.2 mmol) and TBDPSCl (6.2 mL, 23.8 mmol) at room temperature in a nitrogen atmosphere. After 2 h, the mixture was diluted with brine and extracted with ether. The extract was successively washed with water and brine, dried (Na 2 SO 4 ), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc 
(3R,4S)-3-[(tert-Butyldiphenylsilyloxy)methyl]-4-methoxymethoxy-6-hepten-1-yn-3-ol (20) . To a stirred solution of 9 (4.42 g, 10.4 mmol) in CH 2 Cl 2 (100 mL) were successively added solid NaHCO 3 (4.38 g, 52.2 mmol) and DMP (5.74 g, 13.5 mmol) at room temperature in a nitrogen atmosphere. After 25 min, additional NaHCO 3 (5.35 g, 63.6 mmol) and DMP (1.37 g, 3.23 mmol) were added, and the resulting mixture was stirred for 20 min. The mixture was quenched with a mixture of satd. aq. NaHCO 3 , satd. aq. Na 2 S 2 O 3 and water (1:1:1), and then extracted with CH 2 Cl 2 . The extract was washed with brine, dried (Na 2 SO 4 ), and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane/EtOAc ¼ 9:1) to give 10 which was then taken up in THF (88 mL). A solution of bromo(trimethylsilylethynyl)magnesium was prepared by adding EtMgBr (1.0 M in THF, 14.0 mL, 14.0 mmol) to a solution of ethynyltrimethylsilane (2.00 mL, 1.36 mmol) in THF (14 mL) at 0 C and subsequently stirring the resulting mixture at room temperature for 1 h. To the Grignard reagent was added the solution of 10 in THF just obtained at À78 C in a nitrogen atmosphere, and the mixture was gradually warmed to 0 C over 3 h and stirred for an additional 13 h. To the mixture containing 19 were successively added MeOH (100 mL) and K 2 CO 3 (2.88 g, 20.8 mmol), and the mixture was stirred at reflux for 2 h. Since the desilylation was sluggish with the THF/MeOH solvent, these solvents (THF and MeOH) were evaporated, and the residue was diluted with MeOH (100 mL) and mixed with additional (2R/S,4S,5R)-5-[(tert-Butyldiphenylsilyloxy)methyl]-5-ethynyltetrahydrofuran-2,4-diol (27 (2R,3S,5R)-5-(6-Amino-2-fluoropurin-9-yl)-2-[(tert-butyldiphenylsilyloxy)-methyl]-2-ethynyltetrahydrofuran-3-yl acetate (28) . To compound 3 (188 mg, 1.23 mmol) were added a solution of 2d (387 mg, 0.805 mmol) in CH 3 CN (8.0 mL) and BSA (1.10 mL, 4.50 mmol) at room temperature. The mixture was stirred at reflux for 2.5 h and then cooled to 0 C. To the resulting solution was added TMSOTf (0.300 mL, 1.66 mmol), before the mixture was stirred at room temperature for 15 min and then at reflux for an additional 17 h. The mixture was quenched with satd. aq. NaHCO 3 and filtered through a pad of Celite. The filtrate was diluted with water and extracted with CH 2 Cl 2 . The extract was washed with brine, dried (MgSO 4 ), and concentrated in vacuo. 
